CervoMed Inc. Increase (Decrease) in Accrued Liabilities
CervoMed Inc. (CRVO) reported Increase (Decrease) in Accrued Liabilities of -$1.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-07
- CervoMed Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$119.16K, a 116.70% decline year-over-year.
- CervoMed Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.10M.
- CervoMed Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$48.10K, a 123.59% decline year-over-year.
- CervoMed Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $454.08K, a 58.38% decline year-over-year.
- CervoMed Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $834.16K, a 20.84% increase from fiscal 2024.
- CervoMed Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $690.29K, a 46.45% decline from fiscal 2023.
- CervoMed Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $1.29M, a 497.66% increase from fiscal 2022.
- CervoMed Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $215.68K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$119.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$1.22M 10-Q · filed 2026-08-07 | -$1.26M derived: sum of 3 quarters · filed 2026-08-07 | -$810.46K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$1.10M 10-Q · filed 2026-05-15 | -$1.15M derived: sum of 2 quarters · filed 2026-05-15 | -$691.30K derived: sum of 3 quarters · filed 2026-05-15 | $22.30K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$48.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $405.99K derived: sum of 2 quarters · filed 2026-03-13 | $1.12M derived: sum of 3 quarters · filed 2026-08-07 | $834.16K 10-K · filed 2026-03-13 |
| 2025-09-30 | $454.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.17M derived: sum of 2 quarters · filed 2026-08-07 | $882.25K 10-Q · filed 2025-11-07 | $1.09M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $713.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $428.17K 10-Q · filed 2026-08-07 | $632.08K derived: sum of 3 quarters · filed 2026-08-07 | $1.72M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$285.44K 10-Q · filed 2026-05-15 | -$81.53K derived: sum of 2 quarters · filed 2026-05-15 | $1.01M derived: sum of 3 quarters · filed 2026-05-15 | $673.55K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $203.91K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.29M derived: sum of 2 quarters · filed 2026-03-13 | $958.99K derived: sum of 3 quarters · filed 2026-03-13 | $690.29K 10-K · filed 2026-03-13 |
| 2024-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $755.08K derived: sum of 2 quarters · filed 2025-11-07 | $486.38K 10-Q · filed 2025-11-07 | $1.08M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$335.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$604.56K 10-Q · filed 2025-08-08 | -$14.54K derived: sum of 3 quarters · filed 2025-08-08 | $658.39K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$268.70K 10-Q · filed 2025-05-12 | $321.32K derived: sum of 2 quarters · filed 2025-05-12 | $994.25K derived: sum of 3 quarters · filed 2025-05-12 | $655.52K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $590.02K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.26M derived: sum of 2 quarters · filed 2025-03-17 | $924.22K derived: sum of 3 quarters · filed 2025-03-17 | $1.29M 10-K · filed 2025-03-17 |
| 2023-09-30 | $672.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $334.20K derived: sum of 2 quarters · filed 2024-11-12 | $699.01K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$338.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $26.08K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $364.81K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $215.68K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |